Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Eur J Immunol. 2011 Dec 12;42(1):176–185. doi: 10.1002/eji.201141679

Figure 4. TREM-2-deficient DCs show increased maturation in response to TLR agonists.

Figure 4

BMDCs were incubated with CpG DNA (100 nM) or Zymosan (12.5 μg/ml) for 16 h. After incubation, cells were stained with anti-CD11c, anti-CD86 and anti-I-Ab Abs and analyzed by flow cytometry. (A) Plots represent CD11c-positive gated cells. (B, C) The percent of CD86high/I-Abhigh CD11c+ BMDC after 16 h of (B) CpG DNA or (C) Zymosan treatment. Data are represented as mean + SD of triplicate wells. *p<0.05 versus WT, as determined by a one-way ANOVA with Dunnett’s post-test. These data are representative of at least two independent experiments.